Get the Stockscreener App
0.2769
2.33%
-0.0066
Genprex Inc stock is traded at $0.2769, with a volume of 841.69K.
It is down -2.33% in the last 24 hours and down -8.31% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.2835
Open:
$0.2824
24h Volume:
841.69K
Relative Volume:
0.34
Market Cap:
$9.18M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0236
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+0.00%
1M Performance:
-8.31%
6M Performance:
-61.54%
1Y Performance:
-86.02%
1-Day Range:
$0.2695
$0.2857
1-Week Range:
$0.2695
$0.319
52-Week Range:
$0.2023
$3.97
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2769 | 8.03M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Is Genprex Inc. a good long term investmentRobust investment performance - Autocar Professional
Genprex Inc. Stock Analysis and ForecastFree Trend-Following Techniques - Jammu Links News
What drives Genprex Inc. stock priceFree Stock Market Trend Analysis - Jammu Links News
What analysts say about Genprex Inc. stockHigh-margin investment plays - Jammu Links News
Genprex (NASDAQ:GNPX) Stock Price Down 3.2% – Should You Sell? - Defense World
What makes Genprex Inc. stock price move sharplyFree Investment Group - beatles.ru
how genprex inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
How Genprex Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Why Genprex Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
Genprex reports positive results from diabetes gene therapy study By Investing.com - Investing.com Nigeria
Genprex (GNPX) Unveils Promising Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
Genprex Announces Positive Data for Diabetes Therapy - TipRanks
Genprex's Strategic Share Sale: Balancing Dilution Risks with Clinical Milestones - AInvest
Genprex Enters $12.5M Stock Purchase Agreement - TipRanks
Genprex (GNPX) Announces Plan to Sell 15 Million Shares | GNPX Stock News - GuruFocus
Genprex Files for Resale of 15 Million Shares - MarketScreener
genprex regains nasdaq compliance but faces bid price challenge By Investing.com - Investing.com Nigeria
genprex regains nasdaq compliance but faces bid price challenge - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - mx.advfn.com
Genprex (NASDAQ:GNPX) Shares Down 2.8% – Should You Sell? - Defense World
Genprex to Participate at BIO 2025 International Convention - BioSpace
Genprex to Participate at BIO 2025 International Convention | GN - GuruFocus
Genprex to Participate at BIO 2025 International Convention | GNPX Stock News - GuruFocus
Genprex Opens Partnership Discussions for Cancer and Diabetes Gene Therapies at BIO 2025 - Stock Titan
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting | GNPX Stock News - GuruFocus
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Nasdaq
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting | GNPX Stock News - GuruFocus
Genprex (GNPX) Reports Promising Preclinical Data for Diabetes Gene Therapy | GNPX Stock News - GuruFocus
Breakthrough Gene Therapy Could Transform Diabetes Treatment: New Preclinical Data Reveals Promising Results - Stock Titan
What Can Genprex Inc (NASDAQ: GNPX) Expect In 2025? - Stocksregister
WestPark Capital Leads Placement for GNPX | GNPX Stock News - GuruFocus
Genprex (GNPX) to Release Quarterly Earnings on Wednesday - Defense World
Things To Consider Before Buying Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex and University of Pittsburgh sign new agreement to study GPX-002 for diabetes - BioWorld MedTech
Attention Investors: What’s Really Going On With Genprex Inc (NASDAQ: GNPX) - Stocksregister
Genprex Announces Research Agreement for Diabetes Therapy - TipRanks
Genprex (GNPX) Advances Diabetes Therapy Research with New Agreement | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes | GNPX Stock News - GuruFocus
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy - GuruFocus
Genprex (GNPX) Secures Exclusive Patent License for Gene Therapy | GNPX Stock News - GuruFocus
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):